Literature DB >> 35372988

Untangling the Association between Anemia Treatment and Stroke Risk in CKD.

Jay B Wish1.   

Abstract

Entities:  

Keywords:  anemia; chronic kidney disease; dialysis; erythropoietin; hemodialysis; hypoxia-inducible factor; iron; stroke

Mesh：

Substances：

Year:  2021        PMID： 35372988      PMCID： PMC8785830          DOI： 10.34067/KID.0006232021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  9 in total

1.  Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease.

Authors:  Natalie A Bello; Eldrin F Lewis; Akshay S Desai; Inder S Anand; Henry Krum; John J V McMurray; Kurt Olson; Scott D Solomon; Karl Swedberg; Dirk J van Veldhuisen; James B Young; Marc A Pfeffer
Journal:  Eur J Heart Fail       Date:  2015-10-01       Impact factor: 15.534

2.  Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.

Authors:  Patrick S Parfrey; Robert N Foley; Barbara H Wittreich; Daniel J Sullivan; Martin J Zagari; Dieter Frei
Journal:  J Am Soc Nephrol       Date:  2005-05-18       Impact factor: 10.121

3.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

4.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

5.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Authors:  Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

6.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

Authors:  Iain C Macdougall; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; John J V McMurray; Heather Murray; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford
Journal:  N Engl J Med       Date:  2018-10-26       Impact factor: 91.245

7.  Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.

Authors:  Cunlin Wang; Robert Kane; Mark Levenson; Jeffrey Kelman; Michael Wernecke; Joo-Yeon Lee; Steven Kozlowski; Carmen Dekmezian; Zhiwei Zhang; Aliza Thompson; Kimberly Smith; Yu-Te Wu; Yuqin Wei; Yoganand Chillarige; Qin Ryan; Chris Worrall; Thomas E MaCurdy; David J Graham
Journal:  JAMA Intern Med       Date:  2016-12-01       Impact factor: 21.873

8.  Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Jay B Wish; Kai-Uwe Eckardt; Csaba P Kovesdy; Steven Fishbane; Bruce S Spinowitz; Jeffrey S Berns
Journal:  Am J Kidney Dis       Date:  2021-07-28       Impact factor: 8.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.